The Prognostic Role of Cytogenetics Analysis in Philadelphia Negative Myeloproliferative Neoplasms

Overview

Journal Medicina (Kaunas)

Publisher MDPI

Specialty General Medicine

Date 2021 Aug 27

PMID 34441019

Citations 1

Authors

Giuseppe Lanzarone

Matteo Olivi

Affiliations

Soon will be listed here.

Abstract

Myeloproliferative neoplasms (MPNs) are clonal stem cell disorders characterized collectively by clonal proliferation of myeloid cells with variable morphologic maturity and hematopoietic efficiency. Although the natural history of these neoplasms can be measured sometimes in decades more than years, the cytogenetics analysis can offer useful information regarding the prognosis. Cytogenetics has a well-established prognostic role in acute leukemias and in myelodysplastic syndromes, where it drives the clinical decisions. NGS techniques can find adverse mutations with clear prognostic value and are currently included in the prognostic evaluation of MPNs in scores such as MIPSS, GIPSS, MIPSS-PV, and MIPSS-ET. We suggest that cytogenetics (considering its availability and relative cost) has a role regarding prognostic and therapeutic decisions.

Citing Articles

Inflammatory Cytokines Shape an Altered Immune Response During Myeloid Malignancies.

Camacho V, Kuznetsova V, Welner R Front Immunol. 2021; 12:772408.

PMID: 34804065 PMC: 8595317. DOI: 10.3389/fimmu.2021.772408.

References

Wang S, Hasserjian R, Tam W, Tsai A, Geyer J, George T . Bone marrow morphology is a strong discriminator between chronic eosinophilic leukemia, not otherwise specified and reactive idiopathic hypereosinophilic syndrome. Haematologica. 2017; 102(8):1352-1360. PMC: 5541870. DOI: 10.3324/haematol.2017.165340. View

Mukherjee S, Sathanoori M, Ma Z, Andreatta M, Lennon P, Wheeler S . Addition of chromosomal microarray and next generation sequencing to FISH and classical cytogenetics enhances genomic profiling of myeloid malignancies. Cancer Genet. 2017; 216-217:128-141. DOI: 10.1016/j.cancergen.2017.07.010. View

Borovecki A, Skrtic A, Kardum Paro M, Lasan R, Dominis M . [The unclassifiable myeloproliferative neoplasm--morphological, cytogenetic and clinical features]. Acta Med Croatica. 2012; 65 Suppl 1:31-6. View

Sever M, Quintas-Cardama A, Pierce S, Zhou L, Kantarjian H, Verstovsek S . Significance of cytogenetic abnormalities in patients with polycythemia vera. Leuk Lymphoma. 2013; 54(12):2667-70. PMC: 3815965. DOI: 10.3109/10428194.2013.784970. View

Hidaka T, Shide K, Shimoda H, Kameda T, Toyama K, Katayose K . The impact of cytogenetic abnormalities on the prognosis of primary myelofibrosis: a prospective survey of 202 cases in Japan. Eur J Haematol. 2009; 83(4):328-33. DOI: 10.1111/j.1600-0609.2009.01298.x. View

Wolanskyj A, Lasho T, Schwager S, McClure R, Wadleigh M, Lee S . JAK2 mutation in essential thrombocythaemia: clinical associations and long-term prognostic relevance. Br J Haematol. 2005; 131(2):208-13. DOI: 10.1111/j.1365-2141.2005.05764.x. View

Smadja N, Krulik M, de Gramont A, Sirinelli A, Brissaud P, Dray C . Cytogenetic studies in twelve patients with primary myelofibrosis and myeloid metaplasia. Cancer Genet Cytogenet. 1987; 24(1):151-8. DOI: 10.1016/0165-4608(87)90092-6. View

Demory J, Dupriez B, Fenaux P, Lai J, Beuscart R, Jouet J . Cytogenetic studies and their prognostic significance in agnogenic myeloid metaplasia: a report on 47 cases. Blood. 1988; 72(3):855-9. View

Maxson J, Gotlib J, Pollyea D, Fleischman A, Agarwal A, Eide C . Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML. N Engl J Med. 2013; 368(19):1781-90. PMC: 3730275. DOI: 10.1056/NEJMoa1214514. View

10.

Hussein K, Van Dyke D, Tefferi A . Conventional cytogenetics in myelofibrosis: literature review and discussion. Eur J Haematol. 2009; 82(5):329-38. DOI: 10.1111/j.1600-0609.2009.01224.x. View

11.

Andrieux J, Demory J, Caulier M, Agape P, Wetterwald M, Bauters F . Karyotypic abnormalities in myelofibrosis following polycythemia vera. Cancer Genet Cytogenet. 2003; 140(2):118-23. DOI: 10.1016/s0165-4608(02)00678-7. View

12.

Dupriez B, Morel P, Demory J, Lai J, Simon M, Plantier I . Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system. Blood. 1996; 88(3):1013-8. View

13.

Tefferi A, Guglielmelli P, Larson D, Finke C, Wassie E, Pieri L . Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis. Blood. 2014; 124(16):2507-13. PMC: 4199952. DOI: 10.1182/blood-2014-05-579136. View

14.

Bench A, Nacheva E, Champion K, Green A . Molecular genetics and cytogenetics of myeloproliferative disorders. Baillieres Clin Haematol. 2000; 11(4):819-48. DOI: 10.1016/s0950-3536(98)80041-3. View

15.

Chamseddine A, Etancelin P, Penther D, Parmentier F, Kuadjovi C, Camus V . Transformation of an Unclassified Myeloproliferative Neoplasm with a Rare BCR-JAK2 Fusion Transcript Resulting from the Translocation (9;22)(p24;q11). Case Rep Hematol. 2015; 2015:252537. PMC: 4348613. DOI: 10.1155/2015/252537. View

16.

Lishner M, Confino-Cohen R, Mekori Y, Feigin M, Manor Y, GOLDBERG A . Trisomies 9 and 8 detected by fluorescence in situ hybridization in patients with systemic mastocytosis. J Allergy Clin Immunol. 1996; 98(1):199-204. DOI: 10.1016/s0091-6749(96)70243-9. View

17.

Bacher U, Haferlach T, Kern W, Hiddemann W, Schnittger S, Schoch C . Conventional cytogenetics of myeloproliferative diseases other than CML contribute valid information. Ann Hematol. 2005; 84(4):250-7. DOI: 10.1007/s00277-004-0977-1. View

18.

Uppal G, Gong J . Chronic neutrophilic leukaemia. J Clin Pathol. 2015; 68(9):680-4. DOI: 10.1136/jclinpath-2015-203060. View

19.

Cervantes F, Passamonti F, Barosi G . Life expectancy and prognostic factors in the classic BCR/ABL-negative myeloproliferative disorders. Leukemia. 2008; 22(5):905-14. DOI: 10.1038/leu.2008.72. View

20.

Vannucchi A, Antonioli E, Guglielmelli P, Pardanani A, Tefferi A . Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal. Leukemia. 2008; 22(7):1299-307. DOI: 10.1038/leu.2008.113. View